JP5405571B2 - ３−（フェノキシフェニルメチル）ピロリジン化合物 - Google Patents

３−（フェノキシフェニルメチル）ピロリジン化合物 Download PDF

Info

Publication number
JP5405571B2
JP5405571B2 JP2011520186A JP2011520186A JP5405571B2 JP 5405571 B2 JP5405571 B2 JP 5405571B2 JP 2011520186 A JP2011520186 A JP 2011520186A JP 2011520186 A JP2011520186 A JP 2011520186A JP 5405571 B2 JP5405571 B2 JP 5405571B2
Authority
JP
Japan
Prior art keywords
alkyl
halo
compound
alkylene
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011520186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529069A5 (cg-RX-API-DMAC7.html
JP2011529069A (ja
Inventor
エリック エル． スタンジェランド，
ダイク， プリシラ バン
ティモシー ジェイ． チャーチ，
ローリ ジーン パターソン，
ダイスケ ローランド サイトウ，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2011529069A publication Critical patent/JP2011529069A/ja
Publication of JP2011529069A5 publication Critical patent/JP2011529069A5/ja
Application granted granted Critical
Publication of JP5405571B2 publication Critical patent/JP5405571B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011520186A 2008-07-24 2009-07-23 ３−（フェノキシフェニルメチル）ピロリジン化合物 Expired - Fee Related JP5405571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13582808P 2008-07-24 2008-07-24
US61/135,828 2008-07-24
PCT/US2009/051496 WO2010011811A2 (en) 2008-07-24 2009-07-23 3-(phenoxyphenylmethyl)pyrrolidine compounds

Publications (3)

Publication Number Publication Date
JP2011529069A JP2011529069A (ja) 2011-12-01
JP2011529069A5 JP2011529069A5 (cg-RX-API-DMAC7.html) 2012-06-28
JP5405571B2 true JP5405571B2 (ja) 2014-02-05

Family

ID=41078154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011520186A Expired - Fee Related JP5405571B2 (ja) 2008-07-24 2009-07-23 ３−（フェノキシフェニルメチル）ピロリジン化合物

Country Status (7)

Country Link
US (3) US7888386B2 (cg-RX-API-DMAC7.html)
EP (1) EP2318362B1 (cg-RX-API-DMAC7.html)
JP (1) JP5405571B2 (cg-RX-API-DMAC7.html)
AR (1) AR072611A1 (cg-RX-API-DMAC7.html)
ES (1) ES2434250T3 (cg-RX-API-DMAC7.html)
TW (1) TWI438190B (cg-RX-API-DMAC7.html)
WO (1) WO2010011811A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434250T3 (es) * 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
PL2358674T3 (pl) 2008-11-14 2013-06-28 Theravance Inc Sposób otrzymywania związków 4-[2-(2-fluorofenoksymetylo)fenylo]piperydyny
AR075988A1 (es) 2009-04-09 2011-05-11 Lilly Co Eli Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CN102471258A (zh) 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
CN103038211B (zh) 2010-07-09 2015-04-15 施万生物制药研发Ip有限责任公司 3-苯氧基甲基吡咯烷化合物的结晶形式
ES2533434T3 (es) * 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
US10056503B2 (en) * 2016-10-25 2018-08-21 International Business Machines Corporation MIS capacitor for finned semiconductor structure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US363447A (en) * 1887-05-24 axel backsteom
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
AU3898000A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of neuropathic pain or fibromyalgia
DE60019473T2 (de) * 1999-07-01 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
EP1415007A2 (en) * 2001-08-08 2004-05-06 GlaxoSmithKline Biologicals S.A. Method for identification of type specific polynucleotide sequences
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
AU2003269923A1 (en) * 2002-08-23 2004-03-11 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
ES2305776T3 (es) * 2003-06-17 2008-11-01 Pfizer Inc. Derivados de n-pirrolidin-3-il-amida como inhibidores de la re-captacion de serotonina y noradrenalina.
DE602004014823D1 (de) * 2003-12-12 2008-08-14 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
WO2005105763A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2006099468A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the purification of duloxetine hydrochloride
US20090215857A1 (en) 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
EP1886898A2 (en) * 2006-07-31 2008-02-13 Fujikiko Co., Ltd. Variable gear ratio steering device
US20100120858A1 (en) 2006-08-23 2010-05-13 Pfizer Inc. Piperidine Derivatives
ES2434250T3 (es) * 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
AR075988A1 (es) 2009-04-09 2011-05-11 Lilly Co Eli Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
US20100267743A1 (en) 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CN102471258A (zh) 2009-07-13 2012-05-23 施万制药 3-苯氧基甲基吡咯烷化合物
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina

Also Published As

Publication number Publication date
US8242164B2 (en) 2012-08-14
WO2010011811A4 (en) 2010-05-06
EP2318362B1 (en) 2013-09-25
WO2010011811A3 (en) 2010-03-18
AR072611A1 (es) 2010-09-08
US20110275694A1 (en) 2011-11-10
WO2010011811A2 (en) 2010-01-28
EP2318362A2 (en) 2011-05-11
ES2434250T3 (es) 2013-12-16
TW201008912A (en) 2010-03-01
TWI438190B (zh) 2014-05-21
JP2011529069A (ja) 2011-12-01
US20130178509A1 (en) 2013-07-11
US8933249B2 (en) 2015-01-13
US20100022616A1 (en) 2010-01-28
US7888386B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
JP5405571B2 (ja) ３−（フェノキシフェニルメチル）ピロリジン化合物
JP5506813B2 (ja) ４−［２−（２−フルオロフェノキシメチル）フェニル］ピペリジン化合物の結晶形態
JP5826173B2 (ja) ３−フェノキシメチルピロリジン化合物
US8853255B2 (en) 3-phenoxymethylpyrrolidine compounds
JP2012524098A (ja) ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
JP5769348B2 (ja) １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CN103038211A (zh) 3-苯氧基甲基吡咯烷化合物的结晶形式
JP5705239B2 (ja) セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131030

R150 Certificate of patent or registration of utility model

Ref document number: 5405571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees